Loading…

Reduced catalytic activity of human CYP2C9 natural alleles for gliclazide: Molecular dynamics simulation and docking studies

Amongst sulfonylureas, gliclazide is one of the mostly prescribed drugs to diabetic patients and is metabolized extensively by P450 CYP2C9. Among 24-CYP2C9 alleles, the *2/*2 and *3/*3 genotypes showed significantly lower gliclazide clearances with reductions of 25 and 57%, respectively. However, th...

Full description

Saved in:
Bibliographic Details
Published in:Biochimie 2011-06, Vol.93 (6), p.1028-1036
Main Authors: Banu, Hussaina, Renuka, N., Vasanthakumar, Geetha
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c459t-b681ebf3391d6ed1110fe2092c79e81eda429d326a64cbcb7f22aadb181002c83
cites cdi_FETCH-LOGICAL-c459t-b681ebf3391d6ed1110fe2092c79e81eda429d326a64cbcb7f22aadb181002c83
container_end_page 1036
container_issue 6
container_start_page 1028
container_title Biochimie
container_volume 93
creator Banu, Hussaina
Renuka, N.
Vasanthakumar, Geetha
description Amongst sulfonylureas, gliclazide is one of the mostly prescribed drugs to diabetic patients and is metabolized extensively by P450 CYP2C9. Among 24-CYP2C9 alleles, the *2/*2 and *3/*3 genotypes showed significantly lower gliclazide clearances with reductions of 25 and 57%, respectively. However, the reason for the change in drug-metabolizing activity induced by these natural alleles is unknown. In the present study, we used molecular dynamics simulation and autodocking studies to provide models for gliclazide-bound complexes of CYP2C9*2, *3 and *2/*3 mutants, which give insight into CYP2C9–gliclazide interactions and explain the reduced enzymatic activity seen in these variants. Our data shows that the size of the substrate-access entry site is significantly reduced in mutants, which limits the access of gliclazide to heme and the active site. The distance from the substrate oxidation site and heme is >5Å in *3 and *2/*3. Therefore, the addition of an active oxygen molecule by heme-Fe is hindered. The absence of F100, F114 and F476 in the interacting amino acid pocket in *3 reduces catalytic efficiency toward gliclazide. In *1, gliclazide is stabilized by the formation of two hydrogen bonds with R108 while it is absent in mutants. Further in *3 and *2/*3, the key heme-stabilizing residue, R97 stabilization is greatly reduced. Therefore, the decreased catalytic activity of these variants can be explained from the reduced access of the gliclazide to heme, and the interaction between heme and substrate is affected due to their instability in the active site. ► The size of the gliclazide access entry channel to the protein active site is significantly reduced in *3 and *2/*3 mutants. ► The distance between the substrate hydroxylation site and the heme is >5Å in *3 and *2/*3. ► The key residues, F100, F114 and F476, are absent in the interacting amino acid pocket of *3. ► Lack of stability of the active site residues R97 and R108 affects the stability of the heme and gliclazide in *2 and *3. ► Instabilities of heme and gliclazide at the active site affect their interaction, which in turn reduces the activity of mutants.
doi_str_mv 10.1016/j.biochi.2011.02.008
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_899146002</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0300908411000642</els_id><sourcerecordid>863427584</sourcerecordid><originalsourceid>FETCH-LOGICAL-c459t-b681ebf3391d6ed1110fe2092c79e81eda429d326a64cbcb7f22aadb181002c83</originalsourceid><addsrcrecordid>eNqFkU2LFDEQhoMo7rj6D0Ry89S9lXR3JvEgyLB-wIoievAU0kn1bsZ0Z03SCyP-eLPMrkc9FVQ9bxXUQ8hzBi0DJs727eijvfItB8Za4C2AfEA2THSyEUx2D8kGOoBGgexPyJOc9wAwAFePyQln3SC4GDbk9xd0q0VHrSkmHIq31Njib3w50DjRq3U2C919_8x3ii6mrMkEakLAgJlOMdHL4G0wv7zDV_RjDGjXYBJ1h8XM3maa_VwbxceFmsVRF-0Pv1zSXFbnMT8ljyYTMj67q6fk29vzr7v3zcWndx92by4a2w-qNKOQDMep6xRzAh1jDCbkoLjdKqwjZ3quXMeFEb0d7bidODfGjUwyAG5ld0peHvdep_hzxVz07LPFEMyCcc1aKsV6Udn_k6Lr-XaQfSX7I2lTzDnhpK-Tn006aAb6VpDe66MgfStIA9dVUI29uDuwjjO6v6F7IxV4fQSwPuTGY9LZelyqIp_QFu2i__eFPxUepM8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>863427584</pqid></control><display><type>article</type><title>Reduced catalytic activity of human CYP2C9 natural alleles for gliclazide: Molecular dynamics simulation and docking studies</title><source>ScienceDirect Freedom Collection 2022-2024</source><creator>Banu, Hussaina ; Renuka, N. ; Vasanthakumar, Geetha</creator><creatorcontrib>Banu, Hussaina ; Renuka, N. ; Vasanthakumar, Geetha</creatorcontrib><description>Amongst sulfonylureas, gliclazide is one of the mostly prescribed drugs to diabetic patients and is metabolized extensively by P450 CYP2C9. Among 24-CYP2C9 alleles, the *2/*2 and *3/*3 genotypes showed significantly lower gliclazide clearances with reductions of 25 and 57%, respectively. However, the reason for the change in drug-metabolizing activity induced by these natural alleles is unknown. In the present study, we used molecular dynamics simulation and autodocking studies to provide models for gliclazide-bound complexes of CYP2C9*2, *3 and *2/*3 mutants, which give insight into CYP2C9–gliclazide interactions and explain the reduced enzymatic activity seen in these variants. Our data shows that the size of the substrate-access entry site is significantly reduced in mutants, which limits the access of gliclazide to heme and the active site. The distance from the substrate oxidation site and heme is &gt;5Å in *3 and *2/*3. Therefore, the addition of an active oxygen molecule by heme-Fe is hindered. The absence of F100, F114 and F476 in the interacting amino acid pocket in *3 reduces catalytic efficiency toward gliclazide. In *1, gliclazide is stabilized by the formation of two hydrogen bonds with R108 while it is absent in mutants. Further in *3 and *2/*3, the key heme-stabilizing residue, R97 stabilization is greatly reduced. Therefore, the decreased catalytic activity of these variants can be explained from the reduced access of the gliclazide to heme, and the interaction between heme and substrate is affected due to their instability in the active site. ► The size of the gliclazide access entry channel to the protein active site is significantly reduced in *3 and *2/*3 mutants. ► The distance between the substrate hydroxylation site and the heme is &gt;5Å in *3 and *2/*3. ► The key residues, F100, F114 and F476, are absent in the interacting amino acid pocket of *3. ► Lack of stability of the active site residues R97 and R108 affects the stability of the heme and gliclazide in *2 and *3. ► Instabilities of heme and gliclazide at the active site affect their interaction, which in turn reduces the activity of mutants.</description><identifier>ISSN: 0300-9084</identifier><identifier>EISSN: 1638-6183</identifier><identifier>DOI: 10.1016/j.biochi.2011.02.008</identifier><identifier>PMID: 21356265</identifier><language>eng</language><publisher>France: Elsevier B.V</publisher><subject>Alleles ; Aryl Hydrocarbon Hydroxylases - chemistry ; Aryl Hydrocarbon Hydroxylases - genetics ; Aryl Hydrocarbon Hydroxylases - metabolism ; Binding Sites ; Biocatalysis ; Catalytic activity ; Catalytic Domain ; CYP2C92 and 3 ; Cytochrome P-450 CYP2C9 ; Docking simulation ; Enzyme Stability ; Genotype ; Gliclazide ; Gliclazide - chemistry ; Gliclazide - metabolism ; Heme - chemistry ; Humans ; Hydrogen Bonding ; Hydrophobic and Hydrophilic Interactions ; Hydroxylation ; Hypoglycemic Agents - chemistry ; Hypoglycemic Agents - metabolism ; Molecular dynamics ; Molecular Dynamics Simulation ; Mutation ; Natural alleles ; Phenylalanine - chemistry ; Protein Binding ; Protein Structure, Tertiary</subject><ispartof>Biochimie, 2011-06, Vol.93 (6), p.1028-1036</ispartof><rights>2011 Elsevier Masson SAS</rights><rights>Copyright © 2011 Elsevier Masson SAS. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c459t-b681ebf3391d6ed1110fe2092c79e81eda429d326a64cbcb7f22aadb181002c83</citedby><cites>FETCH-LOGICAL-c459t-b681ebf3391d6ed1110fe2092c79e81eda429d326a64cbcb7f22aadb181002c83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21356265$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Banu, Hussaina</creatorcontrib><creatorcontrib>Renuka, N.</creatorcontrib><creatorcontrib>Vasanthakumar, Geetha</creatorcontrib><title>Reduced catalytic activity of human CYP2C9 natural alleles for gliclazide: Molecular dynamics simulation and docking studies</title><title>Biochimie</title><addtitle>Biochimie</addtitle><description>Amongst sulfonylureas, gliclazide is one of the mostly prescribed drugs to diabetic patients and is metabolized extensively by P450 CYP2C9. Among 24-CYP2C9 alleles, the *2/*2 and *3/*3 genotypes showed significantly lower gliclazide clearances with reductions of 25 and 57%, respectively. However, the reason for the change in drug-metabolizing activity induced by these natural alleles is unknown. In the present study, we used molecular dynamics simulation and autodocking studies to provide models for gliclazide-bound complexes of CYP2C9*2, *3 and *2/*3 mutants, which give insight into CYP2C9–gliclazide interactions and explain the reduced enzymatic activity seen in these variants. Our data shows that the size of the substrate-access entry site is significantly reduced in mutants, which limits the access of gliclazide to heme and the active site. The distance from the substrate oxidation site and heme is &gt;5Å in *3 and *2/*3. Therefore, the addition of an active oxygen molecule by heme-Fe is hindered. The absence of F100, F114 and F476 in the interacting amino acid pocket in *3 reduces catalytic efficiency toward gliclazide. In *1, gliclazide is stabilized by the formation of two hydrogen bonds with R108 while it is absent in mutants. Further in *3 and *2/*3, the key heme-stabilizing residue, R97 stabilization is greatly reduced. Therefore, the decreased catalytic activity of these variants can be explained from the reduced access of the gliclazide to heme, and the interaction between heme and substrate is affected due to their instability in the active site. ► The size of the gliclazide access entry channel to the protein active site is significantly reduced in *3 and *2/*3 mutants. ► The distance between the substrate hydroxylation site and the heme is &gt;5Å in *3 and *2/*3. ► The key residues, F100, F114 and F476, are absent in the interacting amino acid pocket of *3. ► Lack of stability of the active site residues R97 and R108 affects the stability of the heme and gliclazide in *2 and *3. ► Instabilities of heme and gliclazide at the active site affect their interaction, which in turn reduces the activity of mutants.</description><subject>Alleles</subject><subject>Aryl Hydrocarbon Hydroxylases - chemistry</subject><subject>Aryl Hydrocarbon Hydroxylases - genetics</subject><subject>Aryl Hydrocarbon Hydroxylases - metabolism</subject><subject>Binding Sites</subject><subject>Biocatalysis</subject><subject>Catalytic activity</subject><subject>Catalytic Domain</subject><subject>CYP2C92 and 3</subject><subject>Cytochrome P-450 CYP2C9</subject><subject>Docking simulation</subject><subject>Enzyme Stability</subject><subject>Genotype</subject><subject>Gliclazide</subject><subject>Gliclazide - chemistry</subject><subject>Gliclazide - metabolism</subject><subject>Heme - chemistry</subject><subject>Humans</subject><subject>Hydrogen Bonding</subject><subject>Hydrophobic and Hydrophilic Interactions</subject><subject>Hydroxylation</subject><subject>Hypoglycemic Agents - chemistry</subject><subject>Hypoglycemic Agents - metabolism</subject><subject>Molecular dynamics</subject><subject>Molecular Dynamics Simulation</subject><subject>Mutation</subject><subject>Natural alleles</subject><subject>Phenylalanine - chemistry</subject><subject>Protein Binding</subject><subject>Protein Structure, Tertiary</subject><issn>0300-9084</issn><issn>1638-6183</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><recordid>eNqFkU2LFDEQhoMo7rj6D0Ry89S9lXR3JvEgyLB-wIoievAU0kn1bsZ0Z03SCyP-eLPMrkc9FVQ9bxXUQ8hzBi0DJs727eijvfItB8Za4C2AfEA2THSyEUx2D8kGOoBGgexPyJOc9wAwAFePyQln3SC4GDbk9xd0q0VHrSkmHIq31Njib3w50DjRq3U2C919_8x3ii6mrMkEakLAgJlOMdHL4G0wv7zDV_RjDGjXYBJ1h8XM3maa_VwbxceFmsVRF-0Pv1zSXFbnMT8ljyYTMj67q6fk29vzr7v3zcWndx92by4a2w-qNKOQDMep6xRzAh1jDCbkoLjdKqwjZ3quXMeFEb0d7bidODfGjUwyAG5ld0peHvdep_hzxVz07LPFEMyCcc1aKsV6Udn_k6Lr-XaQfSX7I2lTzDnhpK-Tn006aAb6VpDe66MgfStIA9dVUI29uDuwjjO6v6F7IxV4fQSwPuTGY9LZelyqIp_QFu2i__eFPxUepM8</recordid><startdate>201106</startdate><enddate>201106</enddate><creator>Banu, Hussaina</creator><creator>Renuka, N.</creator><creator>Vasanthakumar, Geetha</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope><scope>RC3</scope></search><sort><creationdate>201106</creationdate><title>Reduced catalytic activity of human CYP2C9 natural alleles for gliclazide: Molecular dynamics simulation and docking studies</title><author>Banu, Hussaina ; Renuka, N. ; Vasanthakumar, Geetha</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c459t-b681ebf3391d6ed1110fe2092c79e81eda429d326a64cbcb7f22aadb181002c83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Alleles</topic><topic>Aryl Hydrocarbon Hydroxylases - chemistry</topic><topic>Aryl Hydrocarbon Hydroxylases - genetics</topic><topic>Aryl Hydrocarbon Hydroxylases - metabolism</topic><topic>Binding Sites</topic><topic>Biocatalysis</topic><topic>Catalytic activity</topic><topic>Catalytic Domain</topic><topic>CYP2C92 and 3</topic><topic>Cytochrome P-450 CYP2C9</topic><topic>Docking simulation</topic><topic>Enzyme Stability</topic><topic>Genotype</topic><topic>Gliclazide</topic><topic>Gliclazide - chemistry</topic><topic>Gliclazide - metabolism</topic><topic>Heme - chemistry</topic><topic>Humans</topic><topic>Hydrogen Bonding</topic><topic>Hydrophobic and Hydrophilic Interactions</topic><topic>Hydroxylation</topic><topic>Hypoglycemic Agents - chemistry</topic><topic>Hypoglycemic Agents - metabolism</topic><topic>Molecular dynamics</topic><topic>Molecular Dynamics Simulation</topic><topic>Mutation</topic><topic>Natural alleles</topic><topic>Phenylalanine - chemistry</topic><topic>Protein Binding</topic><topic>Protein Structure, Tertiary</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Banu, Hussaina</creatorcontrib><creatorcontrib>Renuka, N.</creatorcontrib><creatorcontrib>Vasanthakumar, Geetha</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><jtitle>Biochimie</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Banu, Hussaina</au><au>Renuka, N.</au><au>Vasanthakumar, Geetha</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Reduced catalytic activity of human CYP2C9 natural alleles for gliclazide: Molecular dynamics simulation and docking studies</atitle><jtitle>Biochimie</jtitle><addtitle>Biochimie</addtitle><date>2011-06</date><risdate>2011</risdate><volume>93</volume><issue>6</issue><spage>1028</spage><epage>1036</epage><pages>1028-1036</pages><issn>0300-9084</issn><eissn>1638-6183</eissn><abstract>Amongst sulfonylureas, gliclazide is one of the mostly prescribed drugs to diabetic patients and is metabolized extensively by P450 CYP2C9. Among 24-CYP2C9 alleles, the *2/*2 and *3/*3 genotypes showed significantly lower gliclazide clearances with reductions of 25 and 57%, respectively. However, the reason for the change in drug-metabolizing activity induced by these natural alleles is unknown. In the present study, we used molecular dynamics simulation and autodocking studies to provide models for gliclazide-bound complexes of CYP2C9*2, *3 and *2/*3 mutants, which give insight into CYP2C9–gliclazide interactions and explain the reduced enzymatic activity seen in these variants. Our data shows that the size of the substrate-access entry site is significantly reduced in mutants, which limits the access of gliclazide to heme and the active site. The distance from the substrate oxidation site and heme is &gt;5Å in *3 and *2/*3. Therefore, the addition of an active oxygen molecule by heme-Fe is hindered. The absence of F100, F114 and F476 in the interacting amino acid pocket in *3 reduces catalytic efficiency toward gliclazide. In *1, gliclazide is stabilized by the formation of two hydrogen bonds with R108 while it is absent in mutants. Further in *3 and *2/*3, the key heme-stabilizing residue, R97 stabilization is greatly reduced. Therefore, the decreased catalytic activity of these variants can be explained from the reduced access of the gliclazide to heme, and the interaction between heme and substrate is affected due to their instability in the active site. ► The size of the gliclazide access entry channel to the protein active site is significantly reduced in *3 and *2/*3 mutants. ► The distance between the substrate hydroxylation site and the heme is &gt;5Å in *3 and *2/*3. ► The key residues, F100, F114 and F476, are absent in the interacting amino acid pocket of *3. ► Lack of stability of the active site residues R97 and R108 affects the stability of the heme and gliclazide in *2 and *3. ► Instabilities of heme and gliclazide at the active site affect their interaction, which in turn reduces the activity of mutants.</abstract><cop>France</cop><pub>Elsevier B.V</pub><pmid>21356265</pmid><doi>10.1016/j.biochi.2011.02.008</doi><tpages>9</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0300-9084
ispartof Biochimie, 2011-06, Vol.93 (6), p.1028-1036
issn 0300-9084
1638-6183
language eng
recordid cdi_proquest_miscellaneous_899146002
source ScienceDirect Freedom Collection 2022-2024
subjects Alleles
Aryl Hydrocarbon Hydroxylases - chemistry
Aryl Hydrocarbon Hydroxylases - genetics
Aryl Hydrocarbon Hydroxylases - metabolism
Binding Sites
Biocatalysis
Catalytic activity
Catalytic Domain
CYP2C92 and 3
Cytochrome P-450 CYP2C9
Docking simulation
Enzyme Stability
Genotype
Gliclazide
Gliclazide - chemistry
Gliclazide - metabolism
Heme - chemistry
Humans
Hydrogen Bonding
Hydrophobic and Hydrophilic Interactions
Hydroxylation
Hypoglycemic Agents - chemistry
Hypoglycemic Agents - metabolism
Molecular dynamics
Molecular Dynamics Simulation
Mutation
Natural alleles
Phenylalanine - chemistry
Protein Binding
Protein Structure, Tertiary
title Reduced catalytic activity of human CYP2C9 natural alleles for gliclazide: Molecular dynamics simulation and docking studies
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-22T10%3A08%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Reduced%20catalytic%20activity%20of%20human%20CYP2C9%20natural%20alleles%20for%20gliclazide:%20Molecular%20dynamics%20simulation%20and%20docking%20studies&rft.jtitle=Biochimie&rft.au=Banu,%20Hussaina&rft.date=2011-06&rft.volume=93&rft.issue=6&rft.spage=1028&rft.epage=1036&rft.pages=1028-1036&rft.issn=0300-9084&rft.eissn=1638-6183&rft_id=info:doi/10.1016/j.biochi.2011.02.008&rft_dat=%3Cproquest_cross%3E863427584%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c459t-b681ebf3391d6ed1110fe2092c79e81eda429d326a64cbcb7f22aadb181002c83%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=863427584&rft_id=info:pmid/21356265&rfr_iscdi=true